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Abstract 
2-agonists are often abused in cattle breeding because of their effects on animal growth and meat 
properties. The use of 2-agonists as growth promoters is forbidden in the European Union (Council 
Directive 96/23/EC classifies them into group A of Annex I), due to their toxicity and carcinogenic 
properties, as for anabolic steroids, which are often administered in combination with 2-agonists, 
to promote the storage of proteins and increase muscle size. 
A unique confirmatory LC-MS/MS method for the quantitative detection of thirteen 2-agonists and 
anabolic steroids plus the qualitative identification of other three analytes in bovine hair was 
developed and validated, according to Decision 2002/657/CE. Hair samples were washed with 
dichloromethane, digested within a NaOH solution, and subjected to liquid–liquid extraction. The 
analysis was performed by HPLC coupled to a triple quadrupole mass spectrometer operating in the 
selected reaction monitoring mode. The absence of matrix interferents, together with good 
repeatability of both retention times and relative abundances of diagnostic transitions, allowed the 
correct identification of all analytes. The quantitative calibrations obtained from spiked blank hair 
samples proved linear in the range tested. CC and CC ranged from 0.5 ng/g to 30 ng/g. 
Intralaboratory reproducibility (CV%) ranged between 5.0 and 17.7 and trueness between 96%±7% 
and 105%±8%. The applicability of the method to real positive samples was demonstrated for both 
2-agonists and anabolic steroids. 
17-boldenone was found in most (70%) hair samples obtained from untreated animals, supporting 
the hypothesis of endogenous production of this steroid. 
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Introduction 
2-agonists are synthetic phenethanolamine compounds used for therapeutic purposes as 
bronchodilator and tocolytic agents. They are structurally similar to the naturally occurring 
catecholamines, such as dopamine, norepinephrine and epinephrine[1]. 2-agonists are usually 
divided into two main sub-classes, that is aniline-like (clenbuterol-like) and phenol-like 
(salbutamol-like) compounds[2]. In the clenbuterol-like compounds, the presence of an amino-group 
accounts for their basic nature. In the salbutamol-like compounds the occurrence of a -hydroxyl 
group produces relatively high polarity, which is amplified when further phenolic or alcoholic 
hydroxyl groups are present in the molecule[3]. 
2-agonists are often abused in cattle breeding[4] because of their growth-promoting effect, produced 
by stimulation of 2-adrenergic receptors on the cell surface. Moreover, they promote protein 
synthesis and cell hypertrophy, by inhibition of proteolysis in the muscle tissue, and induce 
lipolysis in the adipose tissue. These effects may result in a reduction of carcass fat up to 40% and 
an increase of carcass protein content up to 40%, yielding a consistent advantage for the meat 
industry, by increasing the animal lean mass and reducing its fat content. 
In order to obtain these growth-enhancing effects, the applied doses have to be 10-100 times higher 
than necessary for the therapeutic treatment[5,6]. The health risks connected to 2-agonists abuse 
have been underscored by several human poisoning accidents, when the consumption of animal 
food products containing clenbuterol residues was implicated[7]. At the beginning of the ‘90s, some  
cases of human poisoning after ingestion of contaminated liver were reported in Spain[8], France[9], 
and later in Italy[10]. 
2-agonists are occasionally abused in combination with anabolic steroids[4] to enhance further the 
protein storage and increase the muscle size. Due to their toxic and carcinogenic properties[11], the 
non-therapeutic use of both anabolic steroids and 2-agonists has been forbidden in the European 
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Union. Council Directive 96/23/EC classifies 2-agonists and anabolic steroids into group A of 
Annex I – substances having an anabolic effect and unauthorised substances[12]. 
Highly sensitive and reliable analytical methods are necessary to provide evidence of illicit 
pharmaceutical treatments in cattle breeding, and to detect and quantify the presence of trace drug 
residues in biological matrices and food of animal origin. Beside traditional target matrices (urine, 
liver) other less conventional matrices, such as hair and retina, proved to be suitable to detect 
anomalous anabolic steroids or 2-agonists (typically clenbuterol) concentrations. In particular, hair 
analysis offers many advantages: it permits the surveillance of living animals, hair collection is very 
easy and preserves the full exposure history of the animals[13]. Thanks to bioaccumulation, Nielen et 
al. showed that the hair matrix allows largely prolonged detectability of stanozolol, unlike urine[14]. 
Fente et al. detected clenbuterol residues from both therapeutic and growth-promoting treatments in 
hair of a calf until 140 days after the end of the treatment.[15] A few other studies were subsequently 
published, dealing with the determination of either 2-agonists or anabolic steroids in animal hair, 
but the two classes of drugs were never considered together[16-18]. 
Purpose of the present study was to develop and validate a multiresidue analytical method to be 
used in wide-range screening programs for the simultaneous detection of these two classes of drugs 
in bovine hair. The applicability of the whole procedure to real positive hair samples was 
successfully assessed for both classes of drugs. 
 
Materials and methods 
 
Reagent and chemicals 
Clenbuterol, mapenterol hydrochloride, hydroxymethylclenbuterol, tulobuterol hydrochloride, 
bromobuterol hydrochloride, mabuterol hydrochloride, clenpenterol hydrochloride, cimaterol, 
salbutamol, ractopamine hydrochloride, isoxsuprine hydrochloride, 17-boldenone, 17-
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nandrolone, methyltestosterone, methanol, dichloromethane, tert-butyl methyl ether were supplied 
by Sigma–Aldrich (St. Louis, MO, USA). 17-boldenone, 17-nandrolone, 17-nandrolone D3 and 
salbutamol D3 were supplied by Australian Government – National Measurement Institute (Sydney, 
Australia). Clenbuterol D6 was supplied by RIVM (Bilthoven, The Netherlands). 17-boldenone 
D3 was from CDN Isotope (Pointe-Claire, Quebec, Canada). Formic acid 85% was supplied by 
Riedel-de-Haën (Seelze, Germany). Ultrapure water was obtained by a Milli-Q Millipore system 
(Bedford, MA, USA). 
 
Standard solutions  
Stock methanol solutions were prepared at 1 mg mL-1 concentration for all the analytes and internal 
standards (ISs), and then stored in the dark at -20°C. Working methanol solutions containing the 
analytes at different concentrations were prepared by mixing the stock solutions at the proper 
dilution. The working solutions were used to spike negative hair samples at various concentration 
levels. Also a proper mix solution containing all internal standards was prepared. 
 
Negative reference hair samples 
Negative reference hair samples were obtained from 20 strictly non-treated veals from three 
livestock located in Piedmont (Italy). Hair samples were equally distributed between males (9) and 
females (11). All veals were younger than 3.5 months at the moment of sample collection. Hair 
samples were collected from eighteen Piedmontese breed, i.e. the most popular Italian meat breed, 
while two samples were from "Valdostana" veals, a dual-purpose breed (milk and meat)[19]. The 
aspect of different pigmentation was considered in hair selection. Out of 20 hair samples, 7 were 
white, 9 were black, and 4 were brown. 
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Sample preparation 
Hair aliquots of about 200 mg were sampled, transferred into 30 mL glass tubes, and added with 3.0 
mL of dichloromethane to remove the external contamination, paying attention that the whole hair 
lock was completely dipped into the organic solvent. To ease the complete submergence, the tube 
was centrifuged at 3000 rpm (model Megafuge 1.0 Heraeus from ASHI, Milan, Italy), when 
necessary. Otherwise, the tube was just shaken for some seconds with a vortex (model ZX3, Velp 
scientifica, Usmate, Italy) and then introduced into an ultrasound bath (model S 60H Elmasonic, 
Elma, Singen, Germany) for 10 min. After removal of the organic solvent, the decontamination step 
was repeated once more. The cleaned hair was dried under a nitrogen stream, and then cut into tiny 
fragments with clean scissors. An aliquot of 100 mg was exactly weighted, and added with the IS 
mixture solution. Then, an alkaline digestion was performed at 95°C for 10 min, upon addition of 2 
mL NaOH 0.1 M to the hair-containing tube. Then the tube was vortexed for some seconds and 
centrifuged at 3000 rpm for 5 min. After pH adjustment with KH2PO4, 0.1 M (final pH = 8), a 
liquid/liquid extraction was carried out with 2.5 mL of tert-butyl-methyl-ether. The tube was shaken 
vigorously for 5 min by means of a vortex multimixer (Tecnovetro, Monza, Italy) and then 
centrifuged at 3000 rpm for 5 min. The supernatant organic phase was transferred into a 10.0 mL 
glass tube and evaporated to dryness under a gentle stream of nitrogen and mild heating (40°C) 
using a Techne Sample Concentrator (Barloworld Scientific, Stone, UK). The residue was dissolved 
in 50 L of 0.1% p/v aqueous formic acid/methanol mixture 95:5 v/v and transferred into a clean 
vial for the final LC-MS/MS analysis. 
 
LC-MS/MS analysis 
The chromatographic separation was performed on an Agilent 1100 series liquid chromatograph 
(Agilent Technologies, Palo Alto, CA, USA), equipped with a vacuum degasser, a binary pump, an 
autosampler and a column thermostat and using an Agilent XBD C18 column (1.8 m, 4.6  50 
mm). The chromatographic run was carried out by a binary mobile phase of 0.1% aqueous formic 
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acid and methanol, using the following program: isocratic at 5% methanol for 2.5 minutes, linear 
gradient from 5 to 40% methanol in 2.5 minutes, isocratic at 40% methanol for 3.3 minutes, linear 
gradient from 40 to 70% methanol in 2 minutes, isocratic at 70% methanol for 3.7 minutes, linear 
gradient from 70 to 100% methanol in 1 minute, isocratic at 100% methanol for 0.5 minutes, 
isocratic with 5% methanol (equilibration step) for 5.5 minutes. The injection volume was 20 L, 
and the flow rate was 1 mL min-1. The LC was interfaced to an Applied Biosystems API 4000 
triple-quadrupole mass spectrometer (Applied Biosystems Sciex, Ontario, Canada), operating in the 
electrospray ionization (ESI) – positive ion mode. The other MS parameters were set as follows: 
curtain gas: 30 psi; source gas GS1: 40 psi; source gas GS2: 30 psi; probe temperature: 400°C; gas 
for collisional activation: N2 at 4 psi; ion spray voltage: 5000 V; entrance potential: 10 V. Ion 
acquisition was operated at unit mass resolution in the selected reaction monitoring (SRM) mode, 
using for each analyte three transitions from the protonated molecular ion to specific fragment ions 
(see Table 1). 
 
Validation 
The method was fully validated for thirteen target analytes, according to the criteria of Commission 
Decision 2002/657/EC for the forbidden substances confirmatory methods[20]. The evaluated 
parameters included: selectivity, linearity, precision, trueness, decision limit (CC), detection 
capability (CC), ruggedness, absolute recovery, extraction recovery, matrix effect, and evaluation 
of potential ion suppression or enhancement of coeluting analytes. The quantification procedure 
made use of four deuterated ISs: clenbuterol D6, for clenbuterol-like compounds, salbutamol D3, 
for salbutamol-like compounds, 17-boldenone D3 for 17- and 17-boldenone, and 17-
nandrolone D3 for 17- and 17-nandrolone, and methyltestosterone. For the remaining three 
analytes (cimaterol, isoxsuprine and ractopamine), the recommended precision and trueness 
conditions could not be entirely fulfilled, and the present method was validated for screening 
purposes only. 
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Selectivity 
Twenty bovine blank hair samples from as many untreated veals were analyzed as described above. 
The occurrence of possible interferences from endogenous substances was tested by monitoring the 
SRM profiles characteristic for each investigated compound, at the retention time interval expected 
for their elution. The S/N values were expected to be lower than 3, for all SRM transitions. 
 
Linearity 
Instrumental linearity (not prescribed by Decision 2002/657/CE) was studied in order to estimate if 
the method's quantification range lied within the instrumental dynamic linear range. Pure standard 
solutions for each target analyte (two replicates at six concentrations) were analysed by LC-
MS/MS. Slope and intercept were determined by the squares regression method and their 
significance was evaluated with a t-test. The linear fit was verified using adjusted squared 
correlation coefficients (Adj R2).  The Adj R2 was obtained from R2 by taking into account the 
number of observations (calibration points, n) and independent variables (replicates, k): 
Adj R2 = R2 – [(1- R2)/(n-k)]   
Matrix-matched calibration curves were built by analysing two replicates blank hair samples spiked 
with working solutions at four final concentrations. As for instrumental linearity, slope and intercept 
were determined by the squares regression method and their significance was evaluated with a t-
test. The linear fit was verified using Adj R2. 
 
Precision–trueness 
Validation levels were set at 5, 10 and 15 ng/g hair, for clenbuterol, hydroxymethylclenbuterol, 
tulobuterol, bromobuterol, mabuterol and clenpenterol, at 20, 40 and 60 ng/g hair for mapenterol, 
salbutamol and 17-boldenone, and at 50, 100 and 150 ng/g hair for 17-nandrolone, 17-
nandrolone and methyltestosterone. Trueness, repeatability and intra-laboratory reproducibility 
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were estimated by quantifying the analytes in 54 validation replicates (6 replicates for each of the 
three validation levels, repeated after one week and after two weeks), using the IS correction factor. 
ANOVA tests were set for each validation level, from which repeatability and within-laboratory 
reproducibility were evaluated. Precision was estimated from the percent coefficient of variation 
(CV%). 
 
CC and CC 
CC values were calculated using the second method provided by Decision 2002/657/CE: from the 
twenty blank hair samples used to test selectivity, the highest average standard deviation of the 
background signal was considered, and CC was calculated as the concentration yielding a signal 
three-times higher than this background fluctuation. The second most abundant RSM transition for 
each target analyte was used. S/N values were calculated by comparing the peak height at the 
expected retention time for each analyte (signal) and the extremes of fluctuation of the baseline in 
the 12 s following each peak (noise). An extrapolation from the S/N values of the samples spiked at 
the three lowest levels was executed to calculate CC concentrations. These calculated CC were 
rounded up to slightly higher values (i.e., 1, 2, 5 ng/g), which were then experimentally tested and 
confirmed. 
Also CC values were calculated using the second method provided by Decision 2002/657/CE: 
twenty blank materials were fortified with the analytes at the decision limit. The value of the CC 
plus 1,64 times the standard deviation of the within-laboratory reproducibility of the measured 
content provided the CC concentrations 
 
Ruggedness 
A ruggedness test was conducted by introducing slight variations (±10%) to potentially critical 
analytical parameters. The resulting changes in the quantitative response were determined on blank 
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hair samples spiked at the lowest validation level. A Youden approach was used, in which the 
simultaneous change of several experimental parameters was introduced within a 8-experiments 
scheme. The selected parameters were: digestion NaOH volume (1.8-2.2 mL), digestion 
temperature (85-105 °C), digestion time (9-11 min), extraction solvent volume (2.25-2.75 mL), 
multimixer time (9-11 min), centrifugation time (4-6 min) and drying temperature of the extract 
(36–44 °C). 
The significance of the test was verified by calculating the two averages of the results obtained from 
the high- and the low-value setting for each experimental parameter; each average difference (Di) 
was tested against one another to verify their homogeneous distribution. A F-test was applied to 
compare the standard deviation of the differences (SDi) with the standard deviation of the method 
carried out under within-laboratory reproducibility condition (Sr). 
 
Absolute recovery, extraction recovery and matrix effect 
Absolute recovery (that evaluates the contribution of all sample treatments, including the alkaline 
digestion) was calculated by comparing the experimental results of two sets of samples. In the first 
set (a), five blank hair samples were spiked with all analytes at the lowest concentrations used in 
precision-trueness experiments (C0, see above) before the alkaline digestion, while in the second set 
(b) spiking at the same concentration was made on blank hair extracts. For extraction recovery (that 
evaluates only the contribution of the extraction step), the first set (c) consisted of five blank hair 
samples spiked with all analytes at C0 concentration before the extraction step, but after the 
hydrolysis step. Matrix effect was calculated by comparing the second set (b) with a standard 
solution at the same concentration (d). 
 
Ion suppression/enhancement effect of coeluting compounds  
The following analytes showed partial coelution in the chromatographic run: tulobuterol, 
bromobuterol, mabuterol, clenpenterol, and isoxsuprine (see Figure 2). In order to consider the 
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possible presence of more than one analyte in real samples, evaluation of ion 
suppression/enhancement from these co-eluting compounds was made by comparing the 
experimental results from sample set (b) with two further sets of samples. In the first one (e), five 
blank hair extracts were spiked with tulobuterol, mabuterol and isoxsuprine (not coeluting) at C0 
concentration. In the second set (f), five blank hair extracts were spiked with bromobuterol and 
clenpenterol (not coeluting) at C0 concentration. 
 
Results and discussion 
 
Method development 
 
MS optimization 
Three SRM transitions were acquired for the identification of each analyte, so as to exceed the four 
identification points required by Commission Decision 2002/657/CE. The epimers 17-/17-
nandrolone and 17-/17-boldenone were characterized by the same SRM transitions, so that the 
ability to distinguish each epimer was based on their chromatographic peaks separation, which 
proved sufficiently large to go beyond the retention time uncertainty. 
 
Chromatographic optimization 
An important objective of the present work was to obtain the simultaneous determination of 2-
agonists and anabolic steroids (Figure 1) with a single analytical method, despite their considerable 
structural differences. The two classes of analytes are also characterized by a highly dissimilar 
affinity for the most common LC stationary phases. In a previous study, we achieved effective 
separation of all components of both classes of drugs, but the chromatographic method required a 
run time as long as 33 min plus 12 min for column re-equilibration[21]. In order to reduce the time 
needed for the analysis, we presently selected a different column, characterized by a wide internal 
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diameter (4.6 mm) and small particles size (1.8 m). This column supported an high flow, without 
excessive pressure rise, so that good separation could be obtained in a relatively short time: 15 min 
plus 6 min for the re-equilibration step (see Figure 2). Despite the high LC flow, the use of 
methanol and aqueous formic acid solution as mobile phases limited costs and environmental 
concerns. 
 
Sample preparation 
Initial treatment of hair samples generally includes three step: decontamination, digestion and 
extraction. The decontamination step is addressed to prevent the chance of false positive results 
arising from the presence of the analytes on the hair surface due to passive (exogenous) exposure 
not to drug intake. In fact, animals are occasionally exposed to environmental particles, urine or 
feces containing drug residues from authorized veterinary therapies[22]. The adopted procedure 
proved not to extract the drugs present in real positive samples (see below), while it achieved 
effective hair surface decontamination. 
Various procedures for the digestion and extraction of veterinary drugs from hair samples have been 
described. For both -agonists and anabolic steroids, alkaline digestion is most frequently 
used[3,13,15, 18,23]. Other procedures include methanol[16], acidic[24], or aqueous buffer digestion[22]. In 
our optimization of the method, all these four digestion procedures were tested: both alkaline and 
methanol digestions yielded satisfactory results on spiked blank samples, but several authors 
recognized that only alkaline treatment combined with some kind of enzymatic digestion results in 
virtually complete dissolution of the hair structure, while the other treatments cannot assure the total 
drug extraction from the keratin structure[22]. Alkaline treatment, with relatively high base 
concentration and temperature, proved to completely dissolve the hair matrix and give confidence 
that all target analytes were extracted. On the other hand, it was highlighted that such a drastic 
treatment may occasionally result in the production of high background noise and interferences, and 
risk of some analytes’ degradation[25]. The absence of the latter inconvenience was carefully tested 
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by trueness experiments, while the occurrence of major interferences was avoided by submitting the 
digested samples to extraction with tert-butylmethylether, which also allowed to lower the detection 
limits. Since some -agonists, such as salbutamol (but unlike clenbuterol), cannot be satisfactorily 
extracted at high pH values[3], the pH was adjusted to 8, resulting in a quite effective recovery for 
all the analytes considered. 
 
Validation results 
Out of the sixteen target analytes tested, the present analytical protocol was successfully validated 
as a confirmation method, in agreement with Commission Decision 2002/657/EC prescriptions, for 
thirteen substances. The specific case of 17-boldenone, possibly identified as an endogenous 
constituent of bovine hair, is discussed in the subsequent chapter.  
For the remaining three target analytes (cimaterol, isoxysuprine and ractopamine), the validation 
protocol of the method respected Commission Decision 2002/657/EC prescriptions for screening 
methods, not for accurate quantitative determinations. In particular, the latter analytes presented 
CV% values for precision and accuracy exceeding the 20% acceptance limit. Among these, 
isoxsuprine and ractopamine are salbutamol-like drugs with amphoteric properties (see Figure 1), 
due to the presence in their structure of a basic secondary amine group, and one or two acidic 
phenolic hydroxyls. Therefore, the pH has an important influence on the extraction yield. In a 
previous study[21], the dramatic effect of pH on the extraction yield of some -agonists, such as 
salbutamol and terbutaline, has been described in detail, even if the selected experimental pH 
proved to maximize this yield and reduce its variability. In addition, the presence of different matrix 
components are likely to undermine further the extraction repeatability for these amphoteric 
substances.  The use of an isotopically-labeled equivalent as the IS (salbutamol-D3) compensates 
for these fluctuations and allowed us to include salbutamol in the quantitative method. 
On the other hand, salbutamol-like -agonists are not as frequently abused as clenbuterol-like in 
cattle breeding, and are in fact not targeted in most screening procedures. Moreover, the high 
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polarity of salbutamol-like -agonists reduces their binding to melanin[3], which is conversely 
strong for clenbuterol[23]. Similar concepts hold for anabolic steroids, whose accumulation in hair is 
favored by their non-polar structure, due to different incorporation pathways occurring in the 
follicle and hair shaft[26]. 
An overview of the validation results obtained for the analytical method is given in Table 2. For 
cimaterol, isoxysuprine and ractopamine the validation as a screening method includes the 
evaluation of the following parameters: selectivity, CC and ruggedness. These data are reported in 
Table 3. 
 
Selectivity 
The SRM chromatographic profiles obtained from blank hair samples collected from 20 surely 
untreated animals of three reliable livestock did not show the presence of any significant signal 
(S/N<3) at the relative retention time typical of all the studied compounds and ISs, indicating that 
the method is selective and no interfering substances are present in the biological matrices. An 
interesting result is represented by 17-boldenone, as 14 blank hair samples out of 20 turned out 
positive, despite the absence of any pharmacological treatment and the young age of the animals. A 
striking example is reported in Figure 3 (right), where 17-boldenone is apparently present at a 
concentration as high as 16 ng/g. In the remaining 13 samples, where 17-boldenone has been 
determined, its concentration is significantly lower: although the analyte is unequivocally identified, 
its quantification can only be roughly estimated in the 0.5-3.5 ng/g range, below the tested CC 
value.   
The hypothetical occurrence of 17-boldenone as a natural constituent of bovine hair is in 
agreement with the ascertained possibility of its endogenous production, already verified by its 
occasional presence in the urine matrix[27], even if no previous information about its natural 
occurrence in hair is reported in the scientific literature. It is also interesting to note that hair 
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pigmentation apparently affects 17-boldenone incorporation into the keratin matrix, similarly to 
what was observed for clenbuterol,[13] since 100% of black hair (9/9), 50% of brown hair (2/4) and 
only 43% of white hair (4/7) turned out positive to 17-boldenone. 
 
Linearity 
Calibration curves from standard solutions were built by analyzing six increasing concentrations for 
each analyte. The quantification range proved to fall inside the instrumental dynamic linear range. 
The linear matrix-matched calibration model was checked by analyzing two replicate blank hair 
samples spiked with the working solutions at four final concentrations. More in detail, the intervals 
0–15 ng/mL (0, 5, 10 and 15 ng/mL), 0–60 ng/mL (0, 20, 40 and 60) and 0–150 ng/mL (0, 50, 100 
and 150 ng/mL) were investigated for the analytes listed in Table 4. Quantitative data resulting from 
area counts were corrected using the respective IS signal areas. The linear calibration parameters 
were obtained using the least squares regression method. The squared correlation coefficient, 
adjusted by taking into account the number of observations and independent variables (Adj R2), was 
utilized to roughly estimate linearity. The results reported in Table 4 confirm the appropriateness of 
the linear model, which was assessed further by examining the residual plots. 
 
Precision–trueness 
The intra-laboratory reproducibility was expressed by the experimental coefficients of variation, 
that ranged between 5.0% and 17.0%. Decision 2002/657/CE and other international guidelines 
indicate several ways to calculate acceptable CV% limits as a funcion of the analyte concentration. 
The concentrations used to calculate reproducibility (Table 2) ranged from 5 ng/g to 150 ng/g; 
acceptable CV% limits are around 35% for 5 ng/g and around 21% for 150 ng/g, according to 
Horwitz-Thompson equations. Thus, precision values below 20% for all three concentrations tested 
in the present study can be considered satisfactory. Quite similarly, limited bias from true values 
were recorded (-7.2%-+7.2%) at all concentrations, in agreement with Decision 2002/657/CE 
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prescriptions. Taking into account that the IS correction factor exactly compensated for extraction 
yields variability only for four substances (clenbuterol, salbutamol, 17-boldenone, and 17-
nandrolone), the obtainment of reasonable and repeatable concentration assessment for the rest of 
the target analytes represents clear indication of constant recovery yields for these substances. 
 
CC and CC 
 
Calculated CC values ranged between 0.44 and 34.5 ng/g (Table 2). Practical CC values were 
experimentally verified at 0.5 ng/g (Clenbuterol, Hydromethylclenbuterol), 1.0 ng/g (Tulobuterol, 
Bromobuterol, Mabuterol), 2 ng/g (Clenpenterol), 5 ng/g (Mapenterol, Salbutamol, 17-boldenone 
and 17-boldenone), 30 ng/g (17-nandrolone and 17-nandrolone), and 20 ng/g 
(Methyltestosterone). 
The CC values reported for cimaterol, isoxysuprine and ractopamine (Table 3) represent a 
validation requisite for screening methods: at the concentration of 20 ng/g (established and verified 
CC for cimaterol, isoxysuprine, ractopamine the respect of identification criteria was positively 
ascertained. The relative retention time of the analytes corresponded to those recorded from the 
calibration solution with a tolerance lower than ±2.5%. The acceptable tolerance for the relative 
abundance of fragment ions was respected for all analytes and SRM transitions. 
 
Ruggedness 
The quantitative results arising from the experiments planned on the basis of the Youden approach, 
to test the method ruggedness, were interpreted on statistical ground (Table 4). Both t- and F-tests 
showed that no significant changes were induced when limited alteration of the experimental 
parameters were introduced in the sample preparation method. 
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For cimaterol, isoxysuprine and ractopamine, the Youden approach was applied again, in which the 
same eight experiments were performed at the CC level, but only the fulfillment of the 
identification criteria was used to verify the method ruggedness. Also in this case, the method 
proved robust against the selected modifications for screening purposes. 
 
Absolute recovery, extraction recovery and matrix effect 
Absolute recovery, extraction recovery and matrix effect were evaluated and the corresponding 
values are given in Table 5. Extraction recovery values were measured in the range 85%-118%, 
with 6%-19% variability, for all -agonists and anabolic steroids. Absolute recoveries were on 
average 0%-20% lower than extraction recoveries for -agonists, whereas 17α-, 17β-nandrolone, 
and methyltestosterone showed significantly lower absolute recoveries (56%-76%). 
The effect of the real hair matrix appears modest (<6%) and statistically not significant for most -
agonists tested. Slightly larger negative effect (signal suppression) is evident for ractopamine 
(18%). Among anabolic steroids, significant negative matrix effect was detected only for 
methyltestosterone (17%), while modest positive matrix effect was observed for both boldenone e 
nandrolone. 
 
Ion suppression/enhancement effect of co-eluting compounds 
The possible presence of ion suppression/enhancement effects arising from coelution was 
investigated for five partially coeluting analytes (data reported in Table 5). Significant ion 
enhancement effect was observed for bromobuterol and clenpenterol (+22% and +23% 
respectively), while an even more significant ion suppression effect is registered for tulobuterol 
(31%). These effects have to be taken into account, whenever the animals have allegedly been 
treated with multiple -agonist substances. 
 
 19 
Application to real samples 
In order to verify the complete analytical procedure on authentic positive specimens, two hair 
samples involved in real judicial proceedings about suspected illicit treatment were analyzed. The 
washing solutions used in the decontamination procedure were handled and analyzed similarly to 
the sample extracts, and exhibited no presence of the target analytes. Figure 4 shows the SRM 
profiles obtained from the first hair sample, in which clenbuterol was determined at the 
concentration of 11.9 ng/g. 
Analogous SRM profiles are reported in Figure 5, obtained from the second hair sample found 
positive to 17-boldenone at the concentration of 39.0 ng/g. Also in this case, an excellent S/N 
value was obtained from all SRM transitions, allowing clear evidence of the presence of the target 
analyte and its estimated concentration. In the central profiles of Figure 5, also the peaks relative to 
17-boldenone are clearly evident at the expected retention time (13.12 min). Although its 
estimated concentration is extremely high (227 ng/g), its questionable origin makes this finding less 
valuable, as a judicial evidence, than the proven presence of 17-boldenone, even at much lower 
concentration. 
 
Conclusions 
The present analytical methods allows the confirmatory (quantitative) determination of thirteen -
agonists and anabolic steroids simultaneously, and also allows the qualitative identification of 
further three -agonists, in bovine hair. The method has been developed and fully validated 
according to Decision 2002/657/CE. Its applicability to real samples from judicial proceedings has 
also been demonstrated. 
An advantage of the present procedure is that it  is practically used as a routine screening protocol 
targeted to the detection of the illicit administration of both -agonists and anabolic steroids. The 
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single procedure applied on hair samples allows to gain relevant information concerning the 
retrospective use of these drugs on living animals, at reduced costs and increased efficiency. 
Among anabolic steroids, 17-boldenone represents a unique situation, since most hair samples 
from untreated animals that we examined turned out positive to the presence of this steroid. Even if 
its presence has been repeatedly ascertained in the urines of untreated calves, the present study 
provides the first identification of 17-boldenone in the hair of untreated bovines, further 
supporting the hypothesis that this steroid can be produced by endogenous processes. 
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Table 1.  Target analytes are reported with their retention time, precursor and product ions involved in the SRM transition and MS experimental conditions. The 
underlined qualifier product ions are used for CCα calculation. 
 
Class Analyte 
Retention 
time (min) Parent ion 
Quantifier 
product ion 
Qualifier product ions 
(qualifier/quantifier %) 
Declustering 
Potential (V) 
Collision Energy 
(CE) 
Clenbuterol-like 
β2-agonists 
Cimaterol 4.21 219.9 202.1 160.4 (36%); 143.3 (22%) 33 14; 23; 32 
Hydroxymethylclenbuterol 6.10 293.0 203.2 132.0 (32%); 167.1 (12%) 41 26; 41; 37 
Clenbuterol 6.61 277.0 203.1 132.1 (25%); 168.0 (27%) 60 27; 42; 41 
Tulobuterol 6.99 228.1 154.0 172.0 (15%); 117.9 (6%) 93 26; 18; 33 
Bromobuterol 7.06 367.0 293.1 349.2 (38%); 212.2 (24%) 30 25; 16; 42 
Mabuterol 7.12 311.1 236.9 293.4 (34%); 217.1 (31%) 35 23; 18; 36 
Clenpenterol 7.28 291.0 203.0 273.4 (20%); 132.1 (17%) 43 22; 16; 38 
Mapenterol 8.19 325.0 237.2 307.2 (68%); 217.2 (66%) 38 22; 17; 36 
Salbutamol-like  
β2-agonists 
Salbutamol 4.89 240.0 148.0 222.2 (67%); 166.2 (39%) 77 28; 22; 18 
Ractopamine 6.42 302.2 164.1 284.2 (45%); 121.1 (23%) 92 24; 20; 35 
Isoxysuprine 7.34 302.1 284.4 150.3 (61%); 107.4 (51%) 52 20; 31; 41 
Anabolic steroids 
17-/17-boldenone 13.12; 12.42 287.4 121.0 
135.2 54%-87%) ; 173.1 (18%-
30%) 
72 33; 21; 25 
17-/17-nandrolone 13.36; 12.65 275.2 109.1 
257.3 (112%-72%); 239.5 
(32%-22%) 
79 39; 25; 31 
17-methyltestosterone 13.80 303.2 97.2 285.1 (88%); 109.2 (25%) 76 37; 38; 23 
Internal standards 
Salbutamol D3 4.86 243.2 151.0 - 38 26 
Clenbuterol D6 6.59 283.0 203.0 - 45 18 
17-boldenone D3 12.42 290.2 121.2 - 51 34 
17-nandrolone D3 12.65 278.5 109.1 - 65 20 
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Table 2. Intralaboratory reproducibility (CV%), trueness (%), calculated and experimentally verified CCα,(ng/g), reported for thirteen analytes at three concentration values. 
 
 
Intralaboratory reproducibility (CV%) 
(n=18) 
Trueness (%) Mean ± Std Dev (n=18) 
CCα from 20 
blanks 
Verified CCα CC 
Analyte concentration C0 = 5 ng/g 10 ng/g 15 ng/g 5 ng/g 10 ng/g 15 ng/g ng/g ng/g ng/g 
Clenbuterol 8.67 6.88 5.31 105 ± 8 95 ± 6 102 ± 5 0.44 0.5 0.61 
Hydroxymethylclenbuterol 17.0 17.7 7.78 100 ± 9 100 ± 9 100 ± 6 0.52 0.5 0.57 
Tulobuterol 13.3 13.3 6.21 103 ± 8 97 ± 8 101 ± 5 0.78 1 1.26 
Bromobuterol 13.9 14.4 6.69 103 ± 7 97 ± 8 101 ± 5 0.82 1 1.41 
Mabuterol 9.77 10.2 7.56 104 ± 6 96 ± 7 101 ± 7 0.48 1 1.27 
Clenpenterol 8.17 10.3 6.02 103 ± 4 97 ± 7 101 ± 5 1.71 2 2.76 
Analyte concentration C0 = 20 ng/g 40 ng/g 60 ng/g 20 ng/g 40 ng/g 60 ng/g ng/g ng/g ng/g 
Mapenterol 10.7 9.98 7.28 100 ± 7 100 ± 5 100 ± 6 3.47 5 5.99 
Salbutamol 13.1 14.1 6.47 101 ± 8 99 ± 9 100 ± 5 4.00 5 6.11 
17α-boldenone 15.9   95 ± 14   7.62 5 5.69 
17-boldenone 7.38 6.68 5.34 102 ± 5 98 ± 5 101 ± 5 3.38 5 5.79 
Analyte concentration C0 = 50 ng/g 100 ng/g 150 ng/g 50 ng/g 100 ng/g 150 ng/g ng/g ng/g ng/g 
17α-nandrolone 9.08 8.46 5.21 101 ± 5 99 ± 4 100 ± 4 33.1 30 34.6 
17-nandrolone 9.69 9.90 5.00 101 ± 6 99 ± 6 100 ± 4 34.5 30 34.1 
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Table 3. Verification of identification criteria from 20 hair samples spiked at 20 ng/g concentration: experimental CC (ng/g), relative retention time, and relative abundance of 
SRM transitions, for cimaterol, isoxsuprine and ractopamine. 
 
Analyte 
CC(ng/g) 
verified 
 
Relative 
retention time 
Internal standard for 
relative retention time 
calculation 
Relative abundances 
Quantifier 
product ion 
Qualifier product ions 
219.9/202.1 219.9/160.4 219.9/143.3* 
Cimaterol 20 
Reference 0.658 Clenbuterol D6 100% 38% 23% 
Mean±standard deviation (n=20) 0.655±0.007   36%±5% 22%±2% 
     302.1/284.4 302.1/150.3 302.1/107.4* 
Isoxsuprine 20 
Reference 1.514 Salbutamol D3 100% 60% 47% 
Mean±standard deviation (n=20) 1.510±0.013   61%±7% 51%±5% 
     302.2/164.1 302.2/284.2 302.2/121.1* 
Ractopamine 20 
Reference 0.977 Salbutamol D3 100% 48% 20% 
Mean±standard deviation (n=20) 0.975±0.003   45%±6% 23%±2% 
* product ions excluded for CC calculation 
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Table 4. Calibration curves obtained from pure standard solutions (instrumental response linearity) and spiked hair samples (quantitative determinations) with corresponding 
Adjusted R2 values and standard deviation of the differences (SDi),  within-laboratory reproducibility standard deviation (Sr), calculated and critical F values (p = 0.05) for 
ruggedness evaluation.  
Analyte 
Standard solutions Spiked matrix Ruggedness (minor changes) 
Linearity 
range 
(ng/mL) 
Calibration 
curve 
Linearity 
(Adj R2) 
Linearity 
range 
(ng/mL) 
Calibration curve 
Linearity 
(Adj R2) 
Standard 
deviation 
of the 
differences 
(SDi) 
Within-
laboratory 
reproducibility 
standard 
deviation 
(Sr) 
Calculated 
F value 
(Foss) 
Critical 
F value 
(Ftab) 
Clenbuterol 0 – 30 
y = 0.4260 x + 
0.0649 
0.9945 0.5 – 15 
y = 0.5542 x - 
0.1303 
0.9921 0.5649 0.4335 1.3033 
2.9277 
Hydroxymethylclenbuterol 0 – 40 
y = 0.1038 x + 
0.0929 
0.9968 0.5 – 15 
y = 0.2895 x - 
0.0447 
0.9907 0.4085 0.8491 0.4810 
Tulobuterol 0 – 40 
y = 0.3459 x - 
0.3917 
0.9936 1.0 – 15 
y = 0.8301 x - 
0.4849 
0.9853 0.6654 0.4463 1.4909 
Bromobuterol 0 – 40 
y = 0.1314 x - 
0.0733 
0.9823 1.0 – 15 
y = 0.2946 x + 
0.1256 
0.9927 0.4537 0.6930 0.6547 
Mabuterol 0 – 40 
y = 0.3251 x - 
0.0955 
0.9952 1.0 – 15 
y = 0.7499 x - 
0.2543 
0.9919 0.7067 0.4882 1.4475 
Clenpenterol 0 – 30 
y = 0.2851 x - 
0.1329 
0.9932 1.0 – 15 
y = 0.5986 x - 
0.2217 
0.9837 0.5772 0.4084 1.4134 
Mapenterol 0 – 120 
y = 0.2114 x - 
0.8990 
0.9883 5.0 – 60 
y = 0.4661 x + 
0.7085 
0.9879 2.2583 2.1462 1.0522 
Salbutamol 0 – 120 
y = 0.0054 x - 
0.0317 
0.9833 5.0 – 60 
y = 0.0123 x - 
0.0261 
0.9873 2.7708 2.6219 1.0568 
17-boldenone 0 – 120 
Y = 0.0178 x + 
0.0002 
0.9921 5.0 – 60   
Y = 0.0520 x + 
0.0010 
0.9874 2.6478 2.5461 1.0399 
17-boldenone 0 – 120 
y = 0.0179 x - 
0.0280 
0.9921 
5.0 – 60 
y = 0.0266 x + 
0.0493 
0.9874 1.3413 1.4070 0.9533 
17-nandrolone 0 – 300 
y = 0.0188 x - 
0.0093 
0.9915 
30.0 – 
150 
y = 0.0096 x + 
0.0043 
0.9997 3.1549 4.5378 0.6953 
17-nandrolone 0 – 300 
y = 0.0154 x - 
0.0005 
0.9968 
30.0 – 
150 
y = 0.0091 x + 
0.0183 
0.9922 4.7473 4.8445 0.9799 
Methyltestosterone 0 – 300 
y = 0.0192 x - 
0.1400 
0.9828 
20.0 – 
150 
y = 0.0099 x + 
0.0130 
0.9991 3.7549 4.3138 0.8704 
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Table 5. Absolute recovery, extraction recovery, matrix effect and ion suppression/enhancement effect of co-eluting compounds evaluated on five replicates at C0 concentration. 
 
Analyte concentration C0 = 5 ng/g 
Absolute recovery 
(n=5) 
Extraction recovery (n=5) 
Matrix effect 
(n=5) 
Matrix coelution ion enhancement/suppression 
(%) (n=5) 
Clenbuterol 94% ± 11% 102% ± 11% 97% ± 4% 
 
Hydroxymethylclenbuterol 97% ± 6% 97% ± 12% 105% ± 2% 
Tulobuterol 98% ± 7% 98% ± 10% 99% ± 4% 69% ± 5% 
Bromobuterol 75% ± 12% 93% ± 8% 95% ± 4% 122% ± 6% 
Mabuterol 101% ± 12% 118% ± 19% 94% ± 3% 90% ± 7% 
Clenpenterol 94% ± 11% 102% ± 11% 97% ± 4% 123% ± 8% 
Analyte concentration C0 = 20 ng/g  
Mapenterol 80% ± 18% 102% ± 19% 106% ± 5% 
 
Salbutamol 114% ± 8% 94% ± 16% 98% ± 3% 
17-boldenone 104% ± 5% 93% ± 19% 112% ± 5% 
17-boldenone 83% ± 18% 102% ± 6% 102% ± 8% 
Analyte concentration C0 = 50 ng/g  
17-nandrolone 56% ± 9% 108% ± 7% 112% ± 8% 
 17-nandrolone 76% ± 13% 114% ± 9% 101% ± 8% 
Methyltestosterone 56% ± 10% 85% ± 15% 83% ± 9% 
Analyte concentration CC = 20 ng/g  
Cimaterol  94% ± 11%  
Isoxsuprine  95% ± 8% 107% ± 9% 
Ractopamine  82% ± 4%  
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Figure Captions 
 
Figure 1. Structure of anabolic steroids included in the method and general structure of -agonist. 
 
Figure 2. SRM profiles obtained from a standard solution with all the analytes at concentration of 
100 ng/mL.  
 
Figure 3. Chromatographic profiles of the three SRM transitions distinctive for 17and-
boldenone. (Left) Blank hair spiked with 17and17-boldenone at the final concentration of 20 
ng/g. (Right) Unspiked hair sample from an untreated animal: the only peak in the chromatographic 
profile is 17boldenone. Estimated concentration is of 16 ng/g.  
 
Figure 4. Chromatographic profiles of the four SRM transitions distinctive for clenbuterol and the 
single transition distinctive for ISTD clenbuterol D6. (Left) Blank hair spiked with clenbuterol at 
the final concentration of 10 ng/g. (Center) Real hair sample involved in a judicial proceeding about 
suspected illicit treatment (measured clenbuterol concentration: 11.9 ng/g). (Right) Blank hair. 
 
Figure 5. Chromatographic profiles of the three SRM transitions distinctive for 17-boldenone and 
that the single transition distinctive for ISTD 17-boldenone D3. (Left) Blank hair spiked with 17-
boldenone at the final concentration of 40 ng/g. (Center) Real sample involved in a judicial 
proceeding about suspected illicit treatment (measured 17-boldenone concentration:39.0 ng/g). 
(Right) Blank hair. 
 
